| abstract |
Novel purine L-nucleoside compounds are disclosed, in which both the purine ringsnand the sugar are either modified, functionalized or both. The novel compounds ornpharmaceutically acceptable esters or salts thereof may be used in pharmaceuticalncompositions, and such compositions may be used to treat an infection, an infestation, anneoplasm, or an autoimmune disease. The novel compounds may also be used to modulatenaspects of the immune system, including modulation of Th1 and Th2. |